Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 5:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 1,005 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: First Line Therapy Clear all
Completed Phase 2 Interventional

Trial of Ombrabulin (AVE8062) in Combination With Taxane and Platinum in Patients With Non-small Cell Lung Cancer

NCT01263886
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
ombrabulin (AVE8062), placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
5
States / cities
Muscle Shoals, Alabama • Hot Springs, Arkansas • Anaheim, California + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2015 · Synced Oct 22, 2026, 5:50 AM EDT
Completed Phase 3 Interventional Results available

Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)

NCT03260894
View directory record Official record
Conditions
Renal Cell Carcinoma (RCC)
Interventions
Pembrolizumab, Epacadostat, Sunitinib, Pazopanib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
25
States / cities
Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 22, 2026, 5:50 AM EDT
Recruiting Phase 2 Interventional

Carboplatin or Olaparib for BRcA Deficient Prostate Cancer

NCT04038502
View directory record Official record
Conditions
Metastatic Castrate Resistant Prostate Cancer, BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D, or RAD54L Mutations
Interventions
Carboplatin, Olaparib
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
18
States / cities
West Los Angeles, California • Aurora, Colorado • Washington D.C., District of Columbia + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 22, 2026, 5:50 AM EDT
Completed Phase 2 Interventional Results available

Study of Enzastaurin With 5-Fluorouracil/Leucovorin (5-FU/LV) Plus Bevacizumab as Maintenance Regimen Following First Line Therapy for Metastatic Colon Cancer

NCT00612586
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Enzastaurin, Placebo, Leucovorin (LV), 5-fluorouracil (5-FU), Bevacizumab (Bev)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
3
States / cities
Memphis, Tennessee • Houston, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 21, 2020 · Synced Oct 22, 2026, 5:50 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer

NCT05800015
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
fianlimab, cemiplimab, Pemetrexed, Paclitaxel, Carboplatin, Cisplatin, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
29
States / cities
Tucson, Arizona • Yuma, Arizona • Cerritos, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 22, 2026, 5:50 AM EDT
Completed Phase 3 Interventional Results available

Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)

NCT03898180
View directory record Official record
Conditions
Urothelial Carcinoma
Interventions
Pembrolizumab, Lenvatinib, Placebo for lenvatinib
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
505 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
21
States / cities
Gilbert, Arizona • Clovis, California • Orange, California + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 22, 2026, 5:50 AM EDT
Completed Phase 2 Interventional

FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer

NCT01418222
View directory record Official record
Conditions
Colorectal Cancer
Interventions
5-FU, FOLFOX regimen, Placebo, bevacizumab [Avastin], leucovorin, onartuzumab [MetMAb]
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
23
States / cities
San Francisco, California • Denver, Colorado • Fort Myers, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 22, 2026, 5:50 AM EDT
Completed No phase listed Observational

A Comparison of Nivolumab-based Treatments in a Real-world PD-L1 Positive Metastatic Melanoma Population in the US

NCT03732560
View directory record Official record
Conditions
Melanoma
Interventions
Non-Interventional
Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Parsippany, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 8, 2022 · Synced Oct 22, 2026, 5:50 AM EDT
Recruiting Phase 2 Interventional

Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment

NCT05363280
View directory record Official record
Conditions
Small Cell Lung Cancer, Renal Cell Carcinoma (RCC), Non-Small Cell Lung
Interventions
AL8326 40 mg, AL8326 60 mg, AL8326 80 mg--stopped
Drug
Lead sponsor
Advenchen Pharmaceuticals, LLC.
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
5
States / cities
Birmingham, Alabama • Weston, Florida • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 22, 2026, 5:50 AM EDT
Active, not recruiting Phase 1 Interventional

DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers

NCT06132113
View directory record Official record
Conditions
Neuroendocrine Neoplasms
Interventions
BI 764532, Carboplatin, Etoposide, Cisplatin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
5
States / cities
Miami, Florida • Atlanta, Georgia • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 22, 2026, 5:50 AM EDT
Completed Phase 3 Interventional Results available

Anidulafungin Plus Voriconazole Versus Voriconazole For The Treatment Of Invasive Aspergillosis

NCT00531479
View directory record Official record
Conditions
Aspergillosis
Interventions
voriconazole, anidulafungin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
16 Years and older
Enrollment
459 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
26
States / cities
Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2012 · Synced Oct 22, 2026, 5:50 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel

NCT00603941
View directory record Official record
Conditions
Anaplastic Thyroid Cancer
Interventions
CS-7017, Paclitaxel
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
10
States / cities
Aurora, Colorado • Jacksonville, Florida • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Oct 22, 2026, 5:50 AM EDT
Active, not recruiting Phase 2 Interventional

Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma

NCT04643379
View directory record Official record
Conditions
Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma
Interventions
Olaparib, Pembrolizumab, Carboplatin, Peripheral blood draw
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Oct 22, 2026, 5:50 AM EDT
Recruiting Phase 2 Interventional

Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer

NCT06850623
View directory record Official record
Conditions
Locally Advanced Pancreatic Adenocarcinoma
Interventions
Acoustic Cluster Therapy, Modified FOLFIRINOX
Combination Product · Drug
Lead sponsor
EXACT Therapeutics AS
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
7
States / cities
Scottsdale, Arizona • Stanford, California • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 22, 2026, 5:50 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy

NCT03522246
View directory record Official record
Conditions
Epithelial Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancer, Newly Diagnosed, FIGO Stage III-IV, Partial Response, Complete Response
Interventions
Rucaparib, Nivolumab, Placebo Oral Tablet, Placebo IV Infusion
Drug
Lead sponsor
pharmaand GmbH
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,097 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
64
States / cities
Phoenix, Arizona • Tucson, Arizona • Concord, California + 55 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2025 · Synced Oct 22, 2026, 5:50 AM EDT
Completed Phase 1 Interventional

Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Kidney Cancer That is Metastatic or Cannot Be Removed by Surgery

NCT01061411
View directory record Official record
Conditions
Clear Cell Sarcoma of the Kidney, Recurrent Renal Cell Carcinoma, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer
Interventions
Dalteparin, Pharmacological Study, Sunitinib Malate
Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
2
States / cities
Duarte, California • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 5, 2022 · Synced Oct 22, 2026, 5:50 AM EDT
Completed Phase 2 Interventional Results available

Azacitidine and Pembrolizumab in Pancreatic Cancer

NCT03264404
View directory record Official record
Conditions
Pancreas Cancer
Interventions
Pembrolizumab, Azacitidine
Drug
Lead sponsor
Susan E. Bates
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Oct 22, 2026, 5:50 AM EDT
Recruiting Phase 1 Interventional

Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable Metastatic Colorectal Cancer

NCT07500298
View directory record Official record
Conditions
Phase 1, SAR445877, FOlfox6, Bevacizimab, First Line Treatment, Metastatic Colorectal Cancer (CRC), Microsatellite Stable
Interventions
SAR445877, FOLFOX6, Bevacizumab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 22, 2026, 5:50 AM EDT
Completed Phase 3 Interventional Results available

Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)

NCT04003636
View directory record Official record
Conditions
Biliary Tract Carcinoma
Interventions
Pembrolizumab, Gemcitabine, Cisplatin, Placebo
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
1,069 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
18
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Oct 22, 2026, 5:50 AM EDT
Recruiting Phase 3 Interventional

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

NCT06757634
View directory record Official record
Conditions
Breast Cancer
Interventions
Arm A: Gedatolisib + Palbociclib + Fulvestrant, Arm B: Ribociclib + Fulvestrant, Arm C: Gedatolisib + Palbociclib + Letrozole, Arm D: Ribociclib + Letrozole
Drug
Lead sponsor
Celcuity Inc
Industry
Eligibility
18 Years and older
Enrollment
1,180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
30
States / cities
Jonesboro, Arkansas • Little Rock, Arkansas • Duarte, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 22, 2026, 5:50 AM EDT
Completed Phase 1 Interventional

Combination Chemotherapy in Treating Patients With Previously Untreated, Newly Diagnosed Epithelial Tumors

NCT00004082
View directory record Official record
Conditions
Endometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
carboplatin, docetaxel, gemcitabine hydrochloride
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 26, 2013 · Synced Oct 22, 2026, 5:50 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1

NCT04534205
View directory record Official record
Conditions
Unresectable Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer
Interventions
BNT113, Pembrolizumab
Biological
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
15
States / cities
Los Angeles, California • Palo Alto, California • New Haven, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 22, 2026, 5:50 AM EDT
Terminated Phase 2 Interventional Results available

A Study Of Cisplatin (Or Carboplatin) And Etoposide With Or Without Figitumumab (CP-751,871) In Patients With Extensive-Stage Small Cell Lung Cancer

NCT00977561
View directory record Official record
Conditions
Small Cell Lung Carcinoma
Interventions
figitumumab, Cisplatin (Or Carboplatin), Etoposide
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
34
States / cities
Washington D.C., District of Columbia • Marrero, Louisiana • Metairie, Louisiana + 28 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2013 · Synced Oct 22, 2026, 5:50 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer

NCT03742102
View directory record Official record
Conditions
Triple Negative Breast Neoplasms
Interventions
Durvalumab, Capivasertib, Oleclumab, Paclitaxel, Trastuzumab deruxtecan, Datopotamab deruxtecan
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years · Female only
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
8
States / cities
Tucson, Arizona • Columbia, Maryland • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 22, 2026, 5:50 AM EDT